In order to improve the sensitivity of criztinib treatment in NSCLCs, chidamide would downregulate the expression of mRNA m6A methylation regulators WTAP and METTL3, which decreased the expression of c-MET, resulting that crizotinib could sensitize more of NSCLC cells in a c-MET/HGF-dependent manner [56]. This evidence concerns the gene MET and non-small cell lung carcinoma.